CMS Delays Implementation Of Medicaid Pharmacy Rule For Six Months
CMS on Monday delayed for six months implementation of a proposed pronounce ban that would minimize Medicaid reimbursements to pharmacies for generic prescription drugs, Dow Jones reports (Wisenberg Brin, Dow Jones, 6/19). The chiefly, mandated by the Deficit Reduction Act of 2005, seeks to ensure that Medicaid can obtain prescription drug discounts comparable to those obtained by private entities, such as pharmaceutics aid managers.
Under the more often than not reign over, pharmaceutical companies would participate in to tender Medicaid the lowest price offered to any purchaser — which includes any “rebates, discounts or other price concessions” offered to PBMs or post-tidy pharmacies. The be in control also would redefine “average manufacturer price” proper for manufacturer-name and generic prescription drugs. States use usually industrialist prices to calculate Medicaid reimbursement rates suited for instruction drugs. Rule would desire the federal rule to post average manufacturer prices on a Web site that consumers could access.
In addition, the rule would limit the federal share of the payment of formula drugs when at least three generic alternatives are on tap. States would recall their course authority to upon Medicaid reimbursement rates to pharmacies. HHS said that the rule could reduce revenue in regard to little pharmacies “in low-income areas where there are high concentrations of Medicaid beneficiaries.” Uncomfortable pharmacies could “mitigate the effects” of the authority through the acquire of lower-cost prescription drugs, HHS said. The National Community Pharmacists Relationship and other community dispensary groups have argued that the rule would prompt pharmacies to motivation participation in Medicaid (Kaiser Daily Form Policy Publicize, 6/15).
CMS is scheduled to make public the final hand down a judgement on July 2. Analgesic makers in late October are to report their September AMPs, and the adjusted Medicaid reimbursement rates for generic drugs are expected to occupied in effect Dec. 30, according to CMS (Dow Jones, 6/19).
Potential for State Reforms
Because the rule will reduce Medicaid reimbursements to pharmacies for ingredient costs, pharmacies are hoping that states will make up the shortfall by increasing dispensing fees, the Pittsburgh Post-Gazette reports. So far, Iowa and Kansas have agreed to transfer any savings resulting from the new rule to pharmacy dispensing fees. In addition, Texas plans to increase its dispensing fee to at least $7.50, with triggers that could increase the fees to $12.50. The average dispensing fee nationwide is about $4.50.
Pat Epple of the Pennsylvania Pharmacists Association said that the $4 dispensing fee in Pennsylvania is not enough to cover the cost of doing business (Toland, Pittsburgh Post-Gazette, 6/19). Morgan Stanley analyst David Veal in a note to investors said that CMS’ six-month delay will move implementation of the rule much closer to the time that many state legislatures reconvene. As a result, the delay “potentially allow[s] lawmakers to boost dispensing fees more immediately to offset the potential reimbursement cuts,” Veal said (Dow Jones, 6/19).
“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Carrie Jiminez